▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Todd Campbell

tmfebcapital

@ebcapital

Todd has been helping buy side portfolio managers as an independent researcher for over a decade. In 2003, Todd founded E.B. Capital Markets, LLC, a research firm providing action oriented ideas to professional investors. Todd has provided insight to a variety of publications, including SmartMoney, Barron's, and CNN/fn.

Recent Articles by Todd Campbell

Jul 11, 2014 by Todd Campbell

Is This Marijuana Stock GW Pharmaceuticals' Biggest Risk?

Overly optimistic projections could mean that GW Pharma (GWPH) is overpriced.

Jul 11, 2014 by Todd Campbell

1 Drug More Important to Gilead Than Sovaldi

Gilead's Truvada is reshaping HIV treatment globally and may present a bigger opportunity to Gilead than Sovaldi over time.

Jul 11, 2014 by Todd Campbell

Here's What You Need to Know Ahead of Johnson & Johnson's Earnings Report

Here are the key things investors should be considering when Johnson & Johnson (JNJ) reports earnings on July 15th.

Jul 11, 2014 by Todd Campbell

3 Crashing Biotechs: Is 1 a Buy?

Here's why Aegerion (AEGR), Vivus (VVUS), and Exelixis (EXEL) are healthcare's worst performers this year.

Jul 11, 2014 by Todd Campbell

Millions in Obamacare Grants Aim to Revolutionize Healthcare

The Department of Health and Human Services is spending hundreds of millions on innovative solutions designed to boost access to care and improve outcomes.

Jul 10, 2014 by Todd Campbell

Should Sarepta's Shares Be Tumbling?

Sarepta has updated data from eteplirsen's trial in Duchenne's muscular dystrophy, potentially positioning it to compete against Prosensa's drisapersen and PTC Therapeutics Translarna.

Jul 9, 2014 by Todd Campbell

Is Pharmacyclics the Next Celgene?

Pharmacyclics and Johnson & Johnson have a potential blockbuster in Imbruvica that may put Pharmacyclics on a similar path as Celgene.

Jul 8, 2014 by Todd Campbell

Today's 3 Most Volatile Biotech Stocks

Zogenix (ZGNX) and Bluebird bio (BLUE) tumbled today, while TherapeuticsMD (TXMD) made a big move higher.

Jul 8, 2014 by Todd Campbell

Is Opthotech Your Next Multibagger Stock?

Opthotech is working on a treatment for wet AMD that could have sales potential equal to that of Novartis' Lucentis or Regeneron's (REGN) Eylea.

Jul 8, 2014 by Todd Campbell

If AbbVie Buys Shire, Dividend Investors Should Cheer

AbbVie's (ABBV) proposed acquisition of Shire (SHPG) may benefit investors.

Jul 6, 2014 by Todd Campbell

How Urgency Will Save Hospitals

Hospital operators including HCA (HCA) and Tenet Healthcare (THC) are opening urgent care centers to fend off competition from CVS Caremark's (CVS) MinuteClinics and Humana's Concentra.

Jul 6, 2014 by Todd Campbell

1 State's Plan to Fight the AIDS Epidemic

New York has a bold initiative underway to significantly decrease the number of HIV cases diagnosed every year by identifying those most at risk of contacting the disease, and prescribing PrEP therapy using Gilead's (GILD) Truvada.

Jul 6, 2014 by Todd Campbell

The 5 Best Healthcare Stocks so Far in 2014

Intercept, Intermune, Achillion Pharmaceuticals, Accelerate Diagnostics, and Horizon Pharma are among healthcare's best performers this year.

Jul 5, 2014 by Todd Campbell

A New Alliance to Improve Military Health Care

Cerner (CERN), Epic, and Allscripts (MDRX) are all ready to battle over a massive $11 billion contract to modernize the Department of Defense electronic health records system.

Jul 2, 2014 by Todd Campbell

3 Dividend Stocks for Summer: Amgen, Healthcare Services Group, and Quality Systems

Amgen (AMGN), Healthcare Services Group (HCSG), and Quality Systems (QSII) pay solid dividend yields and offer historically strong returns in summer.

Jul 1, 2014 by Todd Campbell

Should AstraZeneca Buy MannKind?

AstraZeneca (AZN) hopes to grow its diabetes revenue in the coming years and could benefit from adding MannKind's Afrezza to its product line up.

Jun 30, 2014 by Todd Campbell

Is AstraZeneca's Dividend Safe?

AstraZeneca faces a stiff patent calendar that could make it a less attractive dividend play than other drugmakers like Pfizer and Bristol Myers.

Jun 30, 2014 by Todd Campbell

3 Stocks Tumbling This Month: Clovis Oncology, Hyperion Therapeutics, and Puma Biotechnology

Puma Biotechnology (PBYI), Clovis Oncology (CLVS), and Hyperion Therapeutics (HPTX) all stumbled by more than 10% in June.

Jun 30, 2014 by Todd Campbell

3 Stocks With Eye-Popping Gains This Month

Achillion, Vital Therapies, and Alder Biopharmaceuticals were among biotech's biggest movers in June.

Jun 29, 2014 by Todd Campbell

Is Obamacare Driving This Surprising Stock?

More than 8 million people have signed up for healthcare through the Affordable Care Act's marketplace, prompting retail clinic operators like Kroger (KR) to open more locations.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services